? DEVELOPMENTAL FUNDS Duke Cancer Institute (DCI) Developmental Funds are instrumental to the DCI strategic research priorities and provide resources to augment its Research Programs and Strategic Initiatives. In the current grant cycle, DCI Developmental Funds, comprised of CCSG, institutional and philanthropic funds, have supported collaborative, translational and novel high-impact pilot projects, recruitment of new investigators, and emerging technologies that promote innovative new research of DCI members. The DCI supports multiple Pilot Grant Programs, including one which alternatively emphasizes collaborative projects (intra-programmatic, inter-programmatic, population science) and translational projects (laboratory discoveries into diagnostic, prognostic, or therapeutic applications), solicited through a ?Request for Applications? (RFA) twice each year. Additionally, DCI has targeted Pilot Grant Programs each year focused on strategic topics, which are supported by multiple sources, including institutional and philanthropic funds. The strategic areas of focus in the current funding period are: i) Cancer Control; ii) Cancer and the Environment; iii) Supportive Care and Survivorship; iv) Comparative Oncology (an external collaboration with the College of Veterinary Medicine at NC State University); v) Solid Tumor Brain Metastasis; vi) BRCA-associated cancers; and vii) collaboration between cancer and engineering research. Faculty recruitment that represents a strategic investment as outlined by the DCI strategic plan and DCI senior leaders are eligible for Developmental Funds as part of their initial recruitment package, or within three years of their faculty appointment. The recruitment funds are made available at any time throughout the year to maintain optimal flexibility in faculty recruitment. Developmental Funds are also available through solicitations offered twice per year for support of a new service line, creation and implementation of a new technique, or a technology investment that enhances existing shared resource services and expands the research tools of DCI investigators. All applications for DCI Developmental Funds are reviewed by the Scientific Review Committee (SRC) or the Shared Resource Oversight Committee (SROC). The DCI Steering Committee is charged with strategic oversight of the DCI Developmental Funds. The final funding decisions are based on assessment of availability of funds and prioritization of strategic investments, with approval by the DCI Executive Director. During this funding period, DCI Developmental Funds were used to support pilot and collaborative projects, recruitment of faculty, and shared resource investment. The $2.9M of CCSG Developmental Funds were augmented by additional $29.4M of institutional/philanthropic funds in all three categories. In the next funding period, CCSG investments will continue to be augmented by institutional and philanthropic funds to advance DCI scientific discoveries, support collaborative working groups and invest in shared resources to ensure DCI members have the necessary services and technologies to achieve the DCI mission and vision.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014236-46
Application #
9853612
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
46
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Abdi, Khadar; Lai, Chun-Hsiang; Paez-Gonzalez, Patricia et al. (2018) Uncovering inherent cellular plasticity of multiciliated ependyma leading to ventricular wall transformation and hydrocephalus. Nat Commun 9:1655
Hudson, Kathryn E; Rizzieri, David; Thomas, Samantha M et al. (2018) Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. Br J Haematol :
Fayanju, Oluwadamilola M; Park, Ko Un; Lucci, Anthony (2018) Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. Ann Surg Oncol 25:512-519
Porter, Laura S; Fish, Laura; Steinhauser, Karen (2018) Themes Addressed by Couples With Advanced Cancer During a Communication Skills Training Intervention. J Pain Symptom Manage 56:252-258
Káradóttir, Ragnhildur T; Kuo, Chay T (2018) Neuronal Activity-Dependent Control of Postnatal Neurogenesis and Gliogenesis. Annu Rev Neurosci 41:139-161
Han, Peng; Liu, Hongliang; Shi, Qiong et al. (2018) Associations between expression levels of nucleotide excision repair proteins in lymphoblastoid cells and risk of squamous cell carcinoma of the head and neck. Mol Carcinog 57:784-793
Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31
Abdi, Khadar; Kuo, Chay T (2018) Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev 32:740-741
Lu, Min; Sanderson, Sydney M; Zessin, Amelia et al. (2018) Exercise inhibits tumor growth and central carbon metabolism in patient-derived xenograft models of colorectal cancer. Cancer Metab 6:14
Qian, Danwen; Liu, Hongliang; Wang, Xiaomeng et al. (2018) Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer :

Showing the most recent 10 out of 513 publications